Desogestrel/ethinyl estradiol,
does it really help with Prevention of pregnancy through ovulation suppression when taken correctly?
research showsDesogestrel/ethinyl estradiol combined oral contraception is rated A because correct and consistent use suppresses ovulation and prevents pregnancy very effectively. In a one-year randomized double-blind multicenter trial of formulations including the Mercilon-like 150-µg/20-µg combination, no method-failure pregnancy occurred over 4,543 cycles in the 20-µg group. Another randomized comparative trial and an 11,656-cycle registration study also found very low Pearl indices. Placebo-controlled contraceptive trials are ethically inappropriate, so efficacy is judged from active-comparator trials, prospective exposure cycles, and use-failure data. Pregnancy is a direct clinical outcome, and the large, consistent effect supports A. The gap between perfect and typical use is driven largely by late or missed pills, while venous thrombosis and smoking- and hypertension-related contraindications remain separate safety issues.
ads claimMarketing may apply a greater-than-99% perfect-use figure to typical use or mix pregnancy prevention with cycle-control and skin claims. Effectiveness is highest when pills are taken consistently, the hormone-free interval and new-pack timing are followed, and missed-pill instructions are applied correctly.
Useful facts when choosing a product
- Mercilon generally contains desogestrel 150 µg and ethinyl estradiol 20 µg in active tablets taken daily on a scheduled cycle, and the exact active-tablet and hormone-free schedule on the product label must be followed.
- Management of a missed pill or delayed new pack depends on the time elapsed and the week of the cycle, so the product instructions or prescriber's advice should be followed and backup contraception used when indicated.
- Vomiting, severe diarrhea, and some hepatic enzyme-inducing medicines can reduce absorption or hormone exposure, and this medicine does not protect against sexually transmitted infections.
- Blood pressure, smoking, migraine aura, thrombotic history, and other cardiovascular risks should be assessed before and during use, and combined hormonal contraception may be contraindicated in smokers aged 35 years or older and in other high-risk groups.
What the research actually shows
The 1993 Akerlund randomized double-blind multicenter trial assigned 1,000 women to desogestrel 150 µg with 20 or 30 µg ethinyl estradiol for one year. There were no method-failure pregnancies in 4,543 cycles with the 20-µg combination and two with the 30-µg combination. The 2001 Endrikat randomized comparison evaluated 890 women and 5,967 cycles and reported no pregnancy in either group, including 2,992 desogestrel/ethinyl estradiol cycles. Walling's United States registration-support study observed 1,221 women for 11,656 cycles without a method-failure pregnancy, although it was uncontrolled and conducted in a registration context. Trussell's synthesis of failure rates emphasizes the large difference between correct, consistent use and typical use. Together these data support a more established preventive effect than time-dependent postcoital emergency contraception.
Why this is classified as A (80)
A one-year randomized double-blind trial of 1,000 women, a randomized comparison of 890 women, and a registration study of 1,221 women assessed direct pregnancy outcomes across nearly 20,000 cycles of desogestrel/ethinyl estradiol exposure and found zero or very few method failures. Pregnancy prevention is a direct outcome and efficacy is very high, but placebo trials are ethically impractical, requiring judgment from Pearl indices and active-comparator and cohort evidence. Old industry-centered product data and poorer adherence in typical use further reduce the score to the bottom of A with 80 points. Venous thrombosis and smoking- and hypertension-related contraindications are safety judgments separate from contraceptive efficacy.
Counterpoint. For someone who expects difficulty taking a daily pill or who uses interacting medicines, a long-acting reversible contraceptive may be more effective in typical use because it is less user-dependent. Progestin-only or nonhormonal options should be compared when thrombotic risk, smoking, migraine, or blood pressure makes estrogen unsuitable.
Rejudgment record. Cross-check revision — Accounted for the ethical impracticality of contraceptive placebo trials and centered the assessment on direct pregnancy outcomes from product-specific randomized active-comparator trials and large prospective exposure cohorts, with deductions for old industry-centered evidence and the perfect-use versus typical-use gap
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Pregnancy prevention with correct and consistent use | A | Product-specific randomized comparisons and large exposure cohorts found zero or very few method-failure pregnancies. |
| Sustained contraceptive efficacy through ovulation suppression | A | Established ovulation suppression by combined estrogen-progestin therapy is supported by direct pregnancy outcomes. |
| Pregnancy prevention in typical use | B | Effectiveness remains substantial, but missed or delayed pills produce a higher failure rate than with perfect use. |
Cross-check — Codex and Claude
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Akerlund M et al. 1993 | One-year randomized double-blind multicenter active-comparator trial | 4,543 | Funding not reported in the PubMed abstract; product-comparison trial | Method-failure and total pregnancy, with cycle control | There were no method-failure pregnancies with desogestrel 150 µg/EE 20 µg and two with the 30-µg formulation. | Key product-specific randomized direct pregnancy evidence |
| Endrikat J et al. 2001 | Prospective multicenter randomized active-comparator trial | 2,992 | Industry product comparison with multiple authors affiliated with Schering AG | Pregnancy occurrence and Pearl Index | Neither the desogestrel/EE group nor the comparator group had a pregnancy, producing a study Pearl Index of zero. | Replication on direct pregnancy outcomes |
| Walling M. 1992 | Large multicenter prospective uncontrolled registration-support study | 879 | Product study supporting United States registration; specific funding not reported in the PubMed abstract | Method-failure pregnancy and Pearl Index | No method-failure pregnancy occurred with desogestrel 150 µg/EE 30 µg exposure. | Large direct exposure evidence with an uncontrolled-design limitation |
| Trussell J. 2011 | Evidence synthesis of first-year contraceptive failure rates | United States NIH/NICHD support | First-year pregnancy failure with perfect and typical use | Combined oral contraceptives have a very low perfect-use failure rate but a higher typical-use rate because of incorrect and inconsistent use. | Real-world applicability adjustment |
Receipt — 5 References
All 5 cited sources were verified for existence at the original page (as of 2026-07-21).
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-21 · Corrections: none
Cite this verdict
[Chamgap] Desogestrel/ethinyl estradiol x pregnancy prevention with correct use — Evidence Grade A·80. 5 cited sources checked. Source: https://chamgap.com/en/verdicts/womens/desogestrel-ethinyl-estradiol-combined-oral-contraception-pregnancy-prevention/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.